Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cornell University
Headquarters: Ithaca, NY, United States of America
Website: http://www.cornell.edu
Year Founded: 1865
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Feb 15, 2025
Discovery & Translation
Science Spotlight: Using HIV to help allogeneic CAR T cells evade immune attack
BioCentury’s roundup of translational innovations also includes a human hypothalamus atlas from Novo and collaborators, and four papers with links to newcos
BioCentury | Jul 18, 2024
Discovery & Translation
Science Spotlight: Preventing NK cells from rejecting allogeneic therapies, and more
BioCentury’s roundup of translational innovations
BioCentury | Feb 24, 2024
Discovery & Translation
Science spotlight: New class of molecular glues, gene therapy for FTD/ALS and more
BioCentury’s roundup of translational innovations
BioCentury | May 24, 2023
Product Development
Lupus consortium could be model for joining FDA, NIH, patients and industry
ARPA-H seeking ideas for collaboration with FDA
BioCentury | May 24, 2023
Finance
May 23 Quick Takes: VCs back cancer play Larkspur with $35.5M
Plus: PTC reports vatiquinone Phase III miss, discontinuation of gene therapies and updates from Innoviva, Pfizer, Wave, Arrowhead, Icosavax and more
BioCentury | Mar 16, 2023
Data Byte
Translational spotlight on variant-proofing tech for COVID and beyond
Host targets and antiviral strategies with efficacy across multiple viruses in BioCentury’s Distillery
BioCentury | Mar 7, 2023
Deals
Amgen deal, $60M round allow Volastra to advance pair of KIF18A products
Licensing deal gives biotech clinical molecule that is more than a year ahead of its former lead synthetic lethality program
BioCentury | Feb 14, 2023
Product Development
Companies queue up gene therapy pipeline
Gene therapy optimism in 1993 had many pegging the advent of marketed products within five years: BioCentury 30th anniversary collection
BioCentury | Oct 14, 2022
Discovery & Translation
Codiak’s pan beta-coronavirus vaccine; plus CNS-penetrating AAV9 variants and more
BioCentury’s roundup of translational news
Items per page:
1 - 10 of 184